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ABSTRACT 
Producing an Ovine Model of Cystic Fibrosis 
by 
Kira P. Morgado, Master of Science 
Utah State University, 2014 
Major Professor: Dr. Kenneth L. White 
Department: Animal, Dairy and Veterinary Sciences 
Cystic Fibrosis (CF) is an autosomal recessive disease that significantly affects 
quality of life and lifespan.  There are currently no effective animal models of CF that 
mimic the human disease state. This prevents the development of pharmaceutical 
treatments for patients.  Sheep have been considered for a useful animal model because 
of their size, life expectancy, and similarities in their anatomy and physiology.  In order 
to generate a sheep transgenic model to study CF we have produced two Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene targeting DNA vectors containing 
large regions of homology to the CFTR gene in sheep.  One of these targeting vectors 
(∆F508Neo) contains sequences designed to delete the phenylalanine at amino acid 
position 508 of CFTR.  Another targeting vector (G27XDTNeo) contains sequences 
designed to introduce an early stop codon into the CFTR gene such that no CFTR is 
produced.  These two targeting vectors were used to transfect White Romney fibroblast 
cells.  Donor sheep oocytes were collected for use in somatic cell nuclear transfer (scNT) 
with the two genetically modified cell lines. Embryos produced from scNT were 
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transferred to recipient ewes which resulted in the birth of 11 ∆F508 heterozygous 
lambs and 3 G27XDT heterozygous lambs.  
(51 pages) 
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PUBLIC ABSTRACT 
Producing an Ovine Model of Cystic Fibrosis 
Kira P. Morgado 
Utah State University, 2014 
 
Cystic Fibrosis (CF) is an autosomal recessive disease that significantly affects 
quality of life and lifespan.  There are currently no effective animal models of CF that 
mimic the human disease state which prevents the development of pharmaceutical 
treatments for patients.  Sheep have been predicted to serve as a useful animal model to 
use because of their size, life expectancy as well as anatomy and physiology.  In order to 
generate a sheep model we will introduce DNA with the CF mutation into White Romney 
sheep cells.  Two mutations will be used for this project, ∆F508 and G27XDT. These 
newly created cell lines will then be used with unfertilized donor sheep eggs in a process 
known as somatic cell nuclear transfer (scNT). During scNT, the nucleus is removed 
from the egg and the donor cell is inserted in its place. This newly formed embryo can be 
transferred into a recipient ewe resulting in an animal with a genetic profile that matches 
that of the cell with the CF mutation. The sheep models that will be produced should 
provide a viable option for studying CF treatments.  This will lead to better treatments 
and improve quality of life for those diagnosed with CF. 
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Cystic Fibrosis (CF) is the most common autosomal recessive disease among 
Caucasians with 1 out of every 2,500 Caucasians affected. Even with significant 
improvements in treatments for patients with CF, it remains a fatal disease (Drumm and 
Collins, 1993).   
CF is caused by mutations in the Cystic Fibrosis Transmembrane Regulator 
(CFTR) gene (Ratjen and Doring, 2003). This gene encodes a glycoprotein that functions 
as a chloride channel located within the apical membranes of epithelial tissue (Engelhardt 
et al., 1994; Ratjen and Doring, 2003; Ballard et al., 2007; Bush and Davies, 2010). To 
date, more than 1,400 gene mutations have been characterized (Alibakhshi et al., 2008) 
with the most common mutation being a deletion of phenylalanine at position 508 
(∆F508) of the CFTR glycoprotein. This particular mutation is responsible for 70% of CF 
cases and is present in 90% of CF patients (Kerem et al., 1989; Shackleton et al.1994; 
Bobadilla et al., 2002; Wang et al., 2000). G27X is a recently discovered and less 
common mutation that is caused by a G-T change at base 211 in exon 2 of the CFTR 
gene. The G27X mutation produces an early stop codon resulting in an absence of CFTR 
protein from epithelial tissue. There is some evidence that suggests that the absence of 
CFTR is less harmful than abnormal protein, making the G27X model useful for 
determining the effects of mutated CFTR (Shackleton and Harris , 1992). Animal models 
have been produced with differing mutations to provide further insight into the link 
between genotype and phenotype of CF (Tebbutt, 1995; Williams et al., 2003; 
Ostedgaard et al., 2007; Fisher et al., 2011; Keiser and Engelhardt, 2011).  
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Pathology resulting from defective CFTR is observed in respiratory, 
gastrointestinal and reproductive systems (Drumm and Collins, 1993; Donaldson and 
Boucher, 2006; Hodges, 2009). The airways and lungs generally have the most severe 
pathology (Quinton,1990; Trezise et al., 1993; Engelhardt et al., 1994). Chronic lung 
infections from sustained bacterial infections lead to respiratory failure and cause more 
than 90% of the mortality in CF patients (Quinton 1990; Cho et al., 2011). The exact 
relationship between the lack of transepithial transport of chloride and the development 
of typical CF lung pathology has not yet been established. This lack of information can 
be partially attributed to ineffective animal models.   
A significant gastrointestinal symptom of CF is meconium ileus. Meconium ileus 
is an intestinal obstruction occurring at birth with a frequency of 13% to 17% of CF 
patients. Severity is variable among patients (Wilschanski and Durie, 1998; van der Doef 
et al., 2011). 
In previous years, the murine model has been the most commonly used CF animal 
model. In 1989, the CFTR gene was first cloned. Three years later a CF mouse model 
was generated (Guilbault et al., 2007). At least 14 mouse models currently exist with 
differing genetic mutations and pathology (Fisher et al., 2011). Undoubtedly, the mouse 
model has contributed greatly to the advancement of CF research (Zeiher et al., 1995). 
However, due to important anatomical and physiological differences between humans 
and mice, this model is limited in its usefulness. The murine model lacks similar 
pathology in the lungs, pancreas and male reproductive tract (Grubb and Boucher, 1999; 
Guilbault et al., 2007; Rogers et al., 2008a; Egan, 2009; Fisher et al., 2011; Keiser and 
Engelhardt, 2011).  
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The high incidence of lung pathology in humans makes differences between 
mouse and human lung pathophysiology critically important. Submucosal glands are the 
primary location of CFTR. In combination with goblet cells, submucosal glands are the 
major producers of mucus within the airways (Engelhardt et al., 1992; Verkman et al., 
2003; Wine and Joo, 2004). Humans have many more submucosal glands in a larger part 
of their airways as compared to mice, which have fewer submucosal glands in a much 
smaller portion of their airways (Liu et al., 2004). Normal mucous production aids in 
ciliary clearance of the lungs. CF patients suffer from an over production of mucous 
which builds up and provides an environment for bacterial growth (Wine and Joo, 2004).   
In patients with CF, chronic lung infections are caused by a small number of 
bacterial pathogens. The most commonly detected bacteria are P aeruginosa, 
Staphylococcus aureus, Haemophilus influenza, and Stenotrophomonas maltophilia. 
These bacterial infections are found in almost all patients with CF and are nearly 
impossible to eradicate (Wine, 1999; Ratjen and Doring, 2003). They lead to an 
inflammatory response that causes lung failure. Chronic infection induced lung failure is 
not observed in mice (Davidson et al., 1995; Liu et al., 2006; Guilbault et al., 2007; 
Keiser et al., 2011), highlighting a shortcoming of the mouse model and the need for a 
better CF model. Researchers have attempted to improve this aspect by exposing mice to 
P. aeruginosa and Staphylococcus aureus. However, such attempts have produced only 
minor improvements to the model (Heeckeren et al., 1997; Davidson et al., 2004). 
Another failure of the mouse model is the lack of a pancreatic phenotype. 
Pancreatic insufficiency is a common ailment of CF patients that affects approximately 
90% of patients (Sturgess, 1984; Quinton, 1999; Rowe et al., 2005). The number of 
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CFTR ion channels in the mouse pancreas is significantly less than in the human 
pancreas. Furthermore, an alternative, calcium activated chloride channel exists in the 
mouse pancreas that is not present in humans. This compensates for a lack of CFTR ion 
channels and results in much less severe pathology (Grubb and Boucher, 1999; Guilbalt 
et al., 2007; Egan, 2009). As a result, the mouse model is less than ideal for studying 
human CF pathophysiology. 
In the case of male fertility, approximately 99% of male CF patients experience 
infertility due to congenital bilateral absence of vas deferens (CBAVD) (Jarzabeck et al., 
2004). In contrast, most mouse models display no pathology in the male reproductive 
tract and have normal fertility rates (Grubb and Boucher, 1999; Bertog et al., 2000; 
Reynaert et al., 2000; Guilbault et al., 2007; Egan, 2009). Female CF mice take longer to 
become pregnant than their healthy counterparts, likely due to abnormal cervical mucus 
(Guilbault et al., 2007; Hodges et al., 2008), but the phenotypes observed in the mouse 
model deviate widely from those observed in humans. In humans, female fertility 
problems are usually mild and occur mostly in those with severe disease (Hodges et al., 
2008; Lau et al., 2010). 
In addition to the lack of comparable pathology in the mouse model, a large 
amount of CF mice die shortly after birth from intestinal blockage. The blockage 
develops after birth and is different than the meconium ileus that is seen in CF patients. 
This pathology is not seen in humans and is problematic in murine CF studies (Grubb and 
Boucher, 1999; Guilbault et al., 2007; Egan, 2009). Despite the great advancements 
provided by the murine model, clearly it is not the most advantageous way to study 
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pathophysiology of CF in humans. This has led researchers to seek for a more 
applicable model.   
Pig and human organs demonstrate anatomical and physiological similarities and 
as a result, pigs have been used as animal models for numerous human diseases 
(Kühholzer et al., 2000; Rogers et al., 2008b; Welsh et al., 2009). Moreover, similarities 
between porcine and human organs are validated by the many studies dedicated to 
developing porcine organs for human xenotransplantation (Cooper et al., 2002). These 
studies have naturally led researchers to believe the porcine model of CF could be a 
viable option. 
The human and porcine CFTR genes are 92% homologous, significantly greater 
than the percent similarity between the human and murine CFTR gene. With a few minor 
exceptions, the general anatomy and structure of porcine lungs parallels that which is 
seen in humans (Rogers et al., 2008a).  
CFTR-null (-/-) and CFTR-ΔF508 piglets were created utilizing adeno-associated 
virus transfection in combination with somatic cell nuclear transfer (scNT). Studies 
conducted after birth show that CFTR
-/-
 piglets lack any CFTR mRNA and expressed no 
protein. Piglets with the ΔF508 mutation (CFTRΔF508/ΔF508 ), however, do maintain 
residual CFTR function but this residual function is not enough to prevent the disease 
phenotype in the piglets (Rogers et al., 2008b; Ostedgaard et al., 2011). 
There are apparent similarities between human and porcine CF phenotypes. Both 
CFTR
-/-
 and CFTR
ΔF508/ΔF508
 piglets developed lung disease at a few months old, 
demonstrating that spontaneous lung infections do occur in the pig model (Rogers et al., 
2008b; Chen et al., 2010; Stoltz et al., 2010; Ostedgaard et al., 2011).   The porcine 
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model also demonstrates abnormalities in the male reproductive tract similar to those 
seen in human CF patients (Pierucci-Alves et al., 2011). 
CFTR
-/-
 piglets were born with severe pancreatic pathology that developed rapidly 
into pancreatic insufficiency while the CFTR
ΔF508/ΔF508
 piglets had a slightly less severe 
phenotype.  This same pattern is observed in the gallbladders of CFTR
-/-
 and 
CFTR
ΔF508/ΔF508
 piglets. CFTR
-/-
 and CFTR
ΔF508/ΔF508
 piglets also showed similar 
pathophysiology to humans in the liver and vas deferens (Rogers et al., 2008c). 
The most pronounced difference between human and porcine CF lies within the 
gastrointestinal tract. Both CFTR
-/-
 and the CFTR
ΔF508/ΔF508
 porcine piglets are born with 
a 100% penetrance of meconium ileus which is a bowel blockage that is fatal unless 
operated upon. The meconium ileus is accompanied by an abnormally small colon, 
known as microcolon. In contrast, approximately 15% of human CF patients are born 
with this condition. It is interesting to note that even though there is residual CFTR in the 
CFTR
ΔF508/ΔF508
 model, 100% of piglets still suffer from meconium ileus. This suggests 
that pigs require a higher level of CFTR than humans in order to maintain healthy 
intestines (Meyerholz et al., 2010; Ostedgaard et al., 2011). 
 While the pig model of CF shows great potential, the 100% rate of meconium 
ileus and the immediate need for surgery postnatally, is a hindrance that prevents the pig 
model from being cost effective and readily maintained.   
Ferret lung anatomy more closely resembles human anatomy than the murine lung 
and has previously been used to study human diseases (Maher and DeStefano, 2004). 
Ferret submucosal glands are found throughout the airways as is seen in humans. The 
expression of CFTR in these submucosal glands is also very similar to the expression 
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seen in human submucosal glands (Sehgal et al., 1996; Li and Engelhardt, 2003; Sun et 
al., 2010; Fisher et al., 2012). 
Genetically, the human and ferret CFTR gene are 91% homologous. The protein 
amino acid identity between the two species is even more striking with a 97% homology 
(Li and Engelhardt, 2003). 
With these commonalities in mind, research moved forward to create a ferret 
model of CF. Advancements in scNT techniques with ferret embryos have facilitated the 
necessary procedures for creating a ferret model of CF.  Current knowledge of ferret CF 
models is derived from CFTR
-/-
 kits. Creating a CFTR
ΔF508/ΔF508
 model will provide more 
insight and understanding of CF pathophysiology in ferrets (Li and Engelhardt, 2003).  
CFTR null ferret kits display meconium ileus with a 75% penetrance. By 36 hours 
postnatal, they displayed significant morbidity and were euthanized 48 hours after birth. 
Microcolon was seen in 30% of the kits born with meconium ileus (Sun et al., 2010; 
Fisher et al., 2011; Keiser et al., 2011).  
The kits that were born without meconium ileus failed to thrive and died within a 
few days of birth. These kits also suffered with early lung infections and elevated liver 
enzymes. Additionally, fat stores were extremely depleted throughout the body. With 
these observations in mind, it is clear that CFTR null kits display the most severe 
gastrointestinal pathology of the currently used CF model species. Ferrets differ from 
previously studied CF models in their carnivorous diet and as a result of their diet, ferrets 
do not have a cecum, an organ that aids in digestion of plant matter. They also have a 
much shorter digestive period than the other species. These differences could account for 
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the severity of gastrointestinal disease that is observed in the CFTR null ferrets (Sun et 
al., 2010). 
In order to alleviate the malabsorption and failure to thrive, a proton-pump 
inhibitor was administered. This is believed to compensate for a diseased pancreas and 
aids in proper digestion.  This resulted in slight weight gain but nonetheless the kits still 
died (Sun et al., 2010).     
The CFTR null kits had pancreatic lesions as seen in human CF (Olivier et al., 
2012).  However, the gross anatomy and histopathology of the liver and gallbladder 
appeared normal, suggesting this model would not be ideal for studying human CF in 
these particular organs. In addition, the vas deferens was absent in 50% of the CFTR null 
kits. The remaining kits had significant degenerate pathology, with parts of the vas 
deferens missing or smaller than normal.    
Despite the major problems observed in the CFTR null kits, abnormal Cl
-
 
permeability and secretions were detected in the submucosal glands of the trachea, 
similar to human CF (Sun et al., 2010; Fisher et al., 2011; Keiser et al., 2011).   
The ferret model of CF has provided some insights into CF pathophysiology. This 
model is still in the early stages of use and further exploration could bring with it more 
information, however, this research will undoubtedly be hindered by the severe pathology 
of the gastrointestinal tract. 
The previously mentioned animal models have the potential to provide advances 
in CF research but there are obvious disadvantages to each model (Ware, 2008). A sheep 
model of CF could provide a viable alternative to the existing CF animal models due to 
genetic and anatomical similarities.  Moreover, the large size and docile nature of sheep 
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allow for easier surgical manipulation.  The longevity of sheep (8-14 years) would 
ensure the ability to better understand long term effects of treatments (Harris, 1997; 
Scheerlinck et al., 2008)  
The human and sheep CFTR genes are 90% homologous as compared with the 
80% homology between the human and mouse CFTR genes. Furthermore, at the protein 
level there is a 95% similarity between human and sheep  proteins, much greater than the 
88% that is observed between human and mouse proteins (Tebbutt et al., 1995). 
Extensive studies on sheep lung epithelium have shown there are striking 
anatomical, functional, and electrophysiological similarities between the human and 
ovine lung. Numerous studies have already used a sheep model to study human lung 
development and pathology and a large part of our understanding of human lung 
physiology has been derived from studies conducted with sheep (Joo et al., 2001; 
Davidson et al., 2006; Scheerlinck et al., 2008; Allen et al., 2009; Abeynaike et al., 2010; 
McLachlan et al., 2011). 
Anatomical similarities include tracheobronchial branching patterns and epithelial 
cell populations (Plopper et al., 1983; Collie et al., 20011). Humans and sheep 
demonstrate dichotomous branching of the bronchi whereas monopodial branching is 
characteristic of mouse lungs (Meeusen et al., 2009). Cells found within the primary and 
secondary bronchioles of sheep include basal, intermediate, ciliated and Clara cells.  The 
location and number of cells within the sheep airways resembles what is observed in 
other mammalian lungs, including that of humans (Emerson et al., 2003).  
Sheep lungs experience inflammation and airway remodeling, a response to 
prolonged inflammation. This further demonstrates similarities between sheep and human 
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respiratory systems (Snibson et al., 2005; Matute-Bello et al., 2008).  A sheep model 
should help alleviate a major drawback to studying CF lung treatments in mice.  The size 
of their lungs and the pattern of breathing in mice greatly differs from the average human.  
Mice are obligate nose breathers, meaning, they are unable to breathe through their 
mouths.  In contrast, sheep lung size and breathing patterns closely replicate human 
anatomy and physiology (Van der Velden and Snibson, 2011).  Sheep are frequently used 
in studies related to breathing patterns in humans (Baier et al., 1985; Haouzi and 
Chennel, 2005).  These similarities are particularly important when considering 
treatments for lung disease because drug delivery to the airways is affected by respiratory 
frequency and breathing volume.  Respiratory rate is dependent on body size and sheep 
lungs are considerably more comparable in size to human lungs (Raeburn et al., 1992; 
Snibson et al., 2005; Meeusen et al., 2009).     
Even without a current CF sheep model, researchers have utilized sheep to study 
CF treatments (Olver and Robinson, 1986; Ferrari et al., 2001; McLachlan et al., 2011). 
These studies validate the usefulness and demonstrate the potential efficiency of a sheep 
model of CF.   
With the help of a sheep model of CF advancements in CF treatments can 
improve quality of life for CF patients, providing relief from an otherwise debilitating 
disease. 
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MATERIALS AND METHODS 
Donor Cell Collection, Culture and Expansion 
All media was purchased from Thermo Scientific (Logan, UT) unless otherwise 
stated. Ear notches were collected from an American Romney sheep.  The biopsies were  
then transported back to the laboratory and used to initiate primary culture in a T-25 flask  
containing DMEM/F12 with 15% fetal bovine serum (FBS), 1X Penicillin Streptomycin  
(PenStrep).  After reaching confluency, the fibroblast cells were treated with trypsin for 5  
minutes. The trypsin was deactivated with 5 mLs DMEM/F12, centrifuged in a 15 mL  
tube at 400 X g and resuspended in DMEM/F12. The cell resuspension was expanded  
into more T-25 flasks.  The subsequent flasks were then frozen in DMEM/F12 with 5%  
DMSO. 
 
 
Bacterial Miniprep 
LB stabs with E. Coli strain K-12 containing plasmids with a construct  
transformed with ∆F508 and the G27XDT mutations respectively, were received from  
Ann Harris at Northwestern University (Figures 1 and 2, shown later). Agar plates were 
streaked with the LB stabs and placed in a 37° C incubator overnight.  Two milliliters of 
LB media with ampicillin was inoculated with a single colony from the streaked agar 
plates.  The tubes with the inoculated broth were placed in a 37° C orbital water bath 
overnight.  The Quicklyse Miniprep Kit from Qiagen was used to extract DNA from the 
inoculated broth.  One and a half milliliters of cultured broth was placed in a 2 mL 
Quicklyse lysis tube.  The broth was pelleted by centrifugation at 17,000 X g for 1 minute 
at room temperature. The media was removed by decanting and 374 μl of ice cold 
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complete lysis solution was added to the pelleted bacterial cells.  The cells were 
vortexed for 30 seconds and incubated at room temperature for 3 minutes. The lysate was 
transferred to a quicklyse spin column by pipetting. It was then centrifuged for 1 minute 
at 17,000 X g. The column was washed by adding 400 μl of diluted Buffer QLW and 
centrifuged for 1 minute at 17,000 X g.  The flow through was discarded and the spin 
column was centrifuged for 1 minute at 17,000 X g to dry the column. The spin column 
was transferred to a new collection tube and 45 μl buffer QLE was added directly to the 
center of the quicklyse spin column.  The column was centrifuged for 1 minute at 17,000 
X g. The DNA concentration was verified via a Nanodrop spectrophotometer and then 
stored at -20° C. 
 
Fibroblast Cell Transfection 
Transfection was performed by electroporation using Invitrogen’s Neon® 
Transfection System. Once ready to perform the transfection, cells were thawed and 
grown in 2 T-25 flasks, one for each construct. At 70% confluency, the cells were 
trypsinized for 5 minutes.  The tryspin was neutralized with DMEM/F12 with 2% FBS in 
a 15 mL conical tube. An aliquot was taken from the neutralized trypsin cell suspension 
and cell density was determined using a hemocytometer.  The cell suspension was 
centrifuged for 5 minutes at 400 X g. The media was decanted and the pelleted cells were 
washed with 1 mL of PBS (without Ca
2+
 and Mg
2+
) and centrifuged for 5 minutes at 400 
X g. The PBS was aspirated and the cell pellet resuspended in Buffer R to a final 
concentration of 1.0 X 10
5
 cells/μL. DNA was prepared by diluting to a concentration of 
100 ng/μl. Six transfection reactions were done for each construct. 
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A 24-well plate was prepared by adding 5 mLs of DMEM/F12 with 15% FBS 
without antibiotic.  The plate was prewarmed in a humidified 37°C/5% CO2 incubator.  
DNA and the cells were combined in a 0.5 mL microfuge tube to a final 
concentration of 1 ug DNA and 1.0 X 10
5
 cells. A neon tube was prepared by adding 3 
mLs of Electrolytic Buffer. A pulse number of 1, pulse width of 20 and voltage of 1600 
was programmed into the device. The combined DNA and cell mixture were pipetted 
using the 10 ul transfection pipette tips and electroporation was performed. Once 
electroporation was completed, cells were placed in the prewarmed culture dishes and 
cultured for 24 hours. 
 
Colony Selection 
Twenty-four hours post transfection, cell media was aspirated and replaced with 
DMEM/F12 with 15% FBS, 800 μg/mL of G418. The media was replaced every other 
day for a total of 2 weeks.  At 2 weeks, non-transfected White Romney cells were 
completely eradicated from G418 treatment.  The wells in the 24-well dish that had 
confluent cells were removed from the well with 0.25% trypsin. The trypsin was 
neutralized with DMEM/F12 with 5% FBS in a 15 mL centrifuge tube.  The cells were 
centrifuged at 400 X g for 5 minutes. The resulting cell pellet was resuspended in 1 mL 
PBS (without Ca
2+
 and Mg
2+
).  The cells were then run through a BD Biosciences Special 
Order FACSAria™ II flow cytometer and sorted into groups of 10, 100, and 1,000.  The 
cells were sorted into a 96-well, flat-bottomed cell culture dish.  Upon reaching 
confluency the cells were trypsinized with 2 drops of 0.25% trypsin for 5 minutes. The 
cells were resuspended in 1.5 mLs of DMEM/F12 with 15% fetal bovine serum (FBS), 
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1X PenStrep.  Cells from each well were grown to confluency and expanded further 
into a 6 well dish.  Once again, at confluency cells were dissociated with 0.25% trypsin.  
Half of the cells were reseeded in a T-25 cell culture flask and the other half were saved 
for DNA extraction.  DNA extraction was performed using the Qiagen DNeasy® Blood 
and Tissue Kit.   
 
Cell DNA Extraction and Sequencing 
DNA extraction was performed using the Qiagen DNeasy® Blood and Tissue Kit. 
Cells were pelleted in a 1.5 mL microfuge tube at 400 X g.  Cell culture media was 
decanted and the pellet was resusupended in 200 μl PBS (without Ca2+ and Mg2+). 
Twenty microliters of Proteinase K was added. Two hundred μl of Buffer AL was added, 
the tube was vortexed and then incubated at 56° C for 10 minutes.  Two hundred 
microliters of Ethanol was added to the tube and it was vortexed and the contents of the 
tube were pipetted into a DNeasy mini spin column placed in a 2 mL collection tube.  It 
was centrifuged at 8000 X g for 1 minute.  The collection tube and flow-through were 
discarded. The spin column was placed in a new collection tube and 500 μl of Buffer 
AW1 was added.  It was centrifuged at 8000 X g for 1 minute.  The collection tube and 
flow-through were discarded. The spin column was placed in a new collection tube.  Five 
hundred microliters of Buffer AW2 was added and the tube centrifuged at 20,000 X g for 
3 minutes.  The collection tube and flow-through were discarded.  The spin column was 
placed in a new 1.5 mL microfuge tube.  One hundred microliters of Buffer AE was 
pipetted directly on the DNeasy membrane.  It was incubated for 1 minute and 
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centrifuged for 1 minute at 8000 X g.  This DNA was submitted for sequencing and 
cells that had the correct mutation were frozen in anticipation of scNT. 
 
 
Somatic Cell Nuclear Transfer  
Animal care and use procedures were conducted by approval of the Utah State 
University Institute of Animal Care and Use Committee. Somatic cell nuclear transfer 
(scNT) cloning procedures were perfomed following our standard laboratory procedures 
(Meng et al., 2011).  Domestic sheep ovaries were collected from an abattoir, Blue 
Mountain Meats in Monticello, Utah. Cumulus-oocyte complexes (COC’s) were 
collected by aspirating 2-8 mm follicles.  Collected oocytes were incubated in maturation 
medium (TCM-199 supplemented with 20% FBS, 25 μg/mL gentamycin, 0.01 U/mL 
FSH, 0.01 U/mL LH) which was pre-equilibrated in a humidified 37°/5% CO2 incubator. 
Oocytes were released from COC’s after 23-24 hours of culture in the formulated 
maturation media.  The transfected fibroblast cells were thawed from cryopreservation 
and cultured in DMEM/F12 with 10% FBS in a humidified 37° C/5% CO2. The cells 
were cultured in the same media with 0.5% FBS for 24 hours before scNT. Just prior to 
scNT, cells were disassociated with 0.25% trypsin and then resuspended in HEPES-
buffered SOF (HSOF).  Oocytes were enucleated by aspirating the first polar body and 
surrounding cytoplasm surrounding cytoplasm in HSOF supplemented with 10 μg/mL 
cytochalasin B (CB).  Then, a single Romney cell was inserted into the perivitelline space 
of an oocyte that has been enucleated.  Fusion of the cell and oocyte was induced by 
double 40 sec 1.8 kV/cm DC pulses in electrofusion medium (0.28M sorbitol in water, 
supplemented with 0.5mM HEPES, 0.1mM Ca(CH3COO)2, 0.5mM Mg(CH3COO)2 and 
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1mg/mL bovine serum albumin).  After fusion, the embryos were incubated in SOFaa 
medium with 5 μg/mL CB for 40-90 minutes and then activated with 5 uM ionomycin for 
5 minutes, followed by treatment with 1 mM 6-dimethylaminopurine (6-DMAP) and 5 
μg/mL cycloheximide (CHX) in SOFaa for 4.5 hours at 38.5° C in 5% CO2 for 1 day and 
transferred to receipents at the 1-cell stage. 
 
Embryo Transfer 
Estrus was synchronized in recipient ewes using vaginal pessaries (Chronogest® 
20 Mg). They were inserted intravaginally on day 0 and removed on day 14.  Twelve 
hours after the removal of the pessaries, the ewes were briefly exposed to a vasectomized 
ram at 2-3 hour intervals and observed for standing heat detection. If a ewe was seen to 
be in heat, the ewe number and time was noted and she was pulled from the group being 
exposed to the vasectomized ram.  
Embryo transfers were performed by exteriorizing the oviduct via midline 
laparotomy. Insertion into the fallopian tube ipsalateral to the side of ovulation was 
accomplished with a Tom Cat catheter (Kendall, 3.5 french, 5.5 open end) attached to a 1 
cc syringe.  
ΔF508 cloned embryos were transferred into two groups of recipients on two 
consecutive days. Western White face ewes were used as recipients on both days. On 
October 11, 2012 one hundred seventy-five embryos were transferred to 10 recipients, 17 
embryos per transfer.  The next day, October 12, 2012, one hundred fifty embryos were 
transferred to 10 recipients, 15 embryos per transfer.  
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G27 embryo transfers also took place on two consecutive days. Suffolk sheep 
were used as recipients for these embryos. Eighty G27 cloned embryos were transferred 
into 4 recipients, 20 embryos per transfer on October 25, 2012. The following day, 
October 26, 2012, one hundred thirty-nine embryos were transferred into 7 recipients.  
A ram with a marking harness was placed with the recipient ewes 30 days after 
embryo transfer to determine if estrus returns. All recipient ewes, including those marked 
by a ram, had an ultrasound scan at 57-60 post transfer. These scans performed via an 
Aloka portable scanner, allowed for assessment of pregnancies.  It was determined that 7 
ΔF508 recipient ewes and 1 G27 recipient ewe were pregnant. Four of the ΔF508 
recipient ewes appeared to be pregnant with twins.  A single G27 recipient ewe also 
appeared to be pregnant with a set of twins. 
 
Embryo Lysis and Sequencing 
On each day of embryo transfer 4-5 embryos were placed in a 0.5 microfuge tube 
in 10 μl of molecular grade water.  Using forceps, the tube was immersed in a canister of 
liquid nitrogen for 1 minute, thawed and immersed again to ensure lysis of the embryos.  
The tube was spun briefly for 30 seconds and 1 μl was used in nested polymerase chain 
reaction resulting in enough DNA to be submitted for sequencing. 
 
Genomic DNA Extraction  
Tissue biopsies were taken from the tails of lambs at birth and transported to the 
laboratory.  In the laboratory they were cleaned with 70% ethanol and rinsed with Hank’s 
Balanced Salt Solution (HBSS).  With a scalpel they were dissected into small pieces and 
added to a 15 mL conical tube containg 5 mLs of 0.25% trypsin.  The tube was placed in 
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a shaking water bath that was prewarmed to 37° C.  The tissue sample was incubated 
in the water bath for 15 minutes with vigorous shaking every 3 minutes.  After 15 
minutes 5 mLs of DMEM/F12 with 5% FBS was added and the tube was centrifuged at 
400 X g for 5 minutes. The media was decanted and the tissue was resuspended in 
DMEM/F12 15% FBS with 1X Amphotericin B (amp-B).  This was transferred to a T-25 
flask where cells were grown until confluency and were then cryopreserved. 
 Small tissue samples (25 mg) were also taken and DNA was extracted using the 
Qiagen DNeasy® Blood and Tissue Kit. The tissue was cut into small pieces and placed 
in a 1.5 mL microfuge tube.  180 ul Buffer ATL and 20 ul proteinase K was added.  The 
tube was vortexed and incubated at 56° C overnight. The next day, the tube was vortexed 
for 15 seconds and 200 μl of Buffer AL was added and it was vortexed again.  Then 200 
μl of 100% ethanol was added and it was vortexed again.  The mixture was pipetted into 
the DNeasy Mini spin column and placed in a 2 ml collection tube. It was centrifuged at 
6,000 X g for 1 minute.  The flow-through and collection tube were discarded. The 
DNeasy Mini spin column was placed in a new 2 mL collection tube and 500 μl of Buffer 
AW1 was added.  The tube was centrifuged at 6,000 X g for 1 minute and the flow-
through and collection tube was discarded. The DNeasy Mini spin column in a new 2 ml 
collection tube and 500 µl Buffer AW2 was added.  It was centrifuged for 3 min at 
20,000 x g. The DNeasy Mini spin column was placed in a clean 1.5 ml microfuge tube 
and 100 μl of Buffer AE was pipetted directly onto the spin column membrane.  It was 
incubated for 1 minute at room temperature and then centrifuge at 20,000 X g for 1 
minute.  The DNA that was extracted was submitted for sequencing at Utah State 
University’s Genomics Laboratory.  
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Homologous Recombination Screening 
Long-range PCR amplification of the targeting constructs was performed with 
DNA from each cloned lamb. For the ΔF508 lambs, the primers FLONGF (5’-
TACCTCTGATACATTTTAAGTTGACT-3’) and FLONGR (5’-
CTCATAATAAATCATACGCAAGCCT-3’) amplified a 2.2 kb fragment of intron 8 of 
the CFTR gene. Each reaction contained 65 ng genomic DNA, a final concentration of .5 
uM of each primer, 12.5 μl of GoTaq® Green Master Mix and Nuclease-free water for a 
final volume of 25 ul. The reaction conditions were 95°C for 5 minutes, then 40 cycles of 
95°C for 30 seconds, 60°C for 2 minutes and 72°C for 2 minutes followed by a final step 
of 72°C for 5 minutes. 
The end-point PCR product should be 2.2 kb. If homologous recombination (HR) 
has occurred in at least one of the CFTR alleles, 1.75 kb of this PCR band will be derived 
from the ΔF508 targeting construct. The ΔF508 targeting construct has a 16 bp deletion 
of intron 8 resulting in the loss of a BglII site.  Thus, PCR products from alleles that have 
undergone HR will not be digested by BglII.  Amplified wild-type DNA will be digested 
by BglII resulting in 1.4 kb and 0.78 kb products (Fig. 1). 
Restriction enzyme digests contained 100 ng of PCR product, 2 μl of 10X 
FastDigest buffer, 1 μl of BglII and H20 to 20 μl.  Reactions were incubated at 37°C for 5 
minutes.  Inactivation was performed by adding 1 μl of 0.5 M EDTA. 
To analyze DNA from the G27 lambs, long-range PCR was performed with the 
primers GLONGF (5’-AGAGGTGAGGGGAAGGGATGG-3’) and GLONGR (5’-
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TGACATCCAACTGCCTTTACCC-3’). This primer pair amplifies the intron 1/exon 
2 region of the CFTR gene and will be 7 kb if the 6.39 kb targeting construct has been 
inserted correctly. The targeting construct contains an engineered Eco RI restriction 
enzyme site. Wild-type DNA would be 5 kb and lack the Eco RI site (Fig. 1). 
PCR utilized Qiagen LongRange PCR kit.  Each reaction contained 5 μl of 
LongRange PCR Buffer, 2.5 μl dNTP mix, 1 ul of each primer, 100 ng of genomic DNA 
and water to reach a final volume of 50 μl.   
The reaction conditions were 93°C for 3 minutes followed by 35 cycles of 93°C 
for 15 seconds, 60°C for 30 seconds and 68°C for 10 minutes. 
After PCR restriction enzyme digests were performed with Eco RI.  Each reaction 
contained 2 μl of FastDigest Buffer, 1 μl Eco RI, 2 μl of PCR product and H20 for a final 
volume of 20 μl. Reactions were incubated at 37°C for 5 minutes and inactivated at 80°C 
for 5 minutes. 
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RESULTS 
Embryo Sequencing 
Embryos not transferred to recipient ewes were lysed two days after the scNT 
procedure and were found to contain the correct sequence for the respective desired 
mutations (Figures 2 and 3).   
 
Ultrasounds 
Of the 20 recipient ewes that received ΔF508 scNT embryos, 10 were marked 
open by the vasectomized teaser ram, which indicated they were not pregnant following 
embryo transfer and had returned to estrus. 5 of the 11 G27 recipients were also marked 
open by the ram.  
Seven ΔF508 recipient ewes and 1 G27 recipient ewe were pregnant following 
ultrasound. Four of the ΔF508 recipient ewes were diagnosed as having twins.  A single 
G27 recipient ewe was pregnant with twins. 
 
Birth of Lambs 
There were 11 ΔF508 lambs born.  All of the lambs cloned from this cell line 
exhibited multiple congenital abnormalities that were incompatible with life (Table 1). 
Most notably, 10 of the 11 lambs had severe palatoschisis (cleft palate) of both the hard 
and soft palate.  The lamb without a cleft palate was stillborn.  
 Three G27X lambs were born.  None of the G27X lambs had a cleft palate.  The 
phenotype of the G27X lambs was much less severe than was seen in the ΔF508 lambs 
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(Table 2).  One was stillborn, the second G27X lamb born died from a lung infection, 
and the third lamb born remains alive.   
 DNA extracted from lamb tissues was sequenced with an ABI PRISM™ 3730 
DNA Analyzer using BigDye terminator chemistry. This genetic analysis showed that 
nine ΔF508 lambs were heterozygous for the ΔF508 mutation and two were homozygous.   
Both ΔF508 homozygous lambs were stillborn and too necrotic for a complete 
necropsy of internal tissues. One of the ΔF508 homozygous lambs did not have a cleft 
palate, the other one did. 
 DNA sequencing of the G27X lambs showed they were all heterozygous for the 
G27X mutation.  
 
Homologous Recombination Screening 
 PCR product from ΔF508 cloned lambs digested with BglII resulted in 2 bands 
sized at 1.4 kb and 0.78 kb (Fig. ).  These results demonstrate that the BglII was still 
present and homologous recombination did not occur. 
 PCR product from G27 digested with EcoRI had only one band sized at 5 kb. This 
demonstrates that HR did not occur as there was no EcoRI site present. It can also be 
concluded that the 6.39 kb targeting construct was not inserted correctly as the band size 
was not large enough for the targeting construct to be present. 
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Figure 1. Diagrams of the ΔF508 and G27 targeting vectors.  The neomycin cassette and 
long range PCR primers are shown.  The Diptheria Toxin A gene is not shown because it 
should be removed after homologous recombination. Restriction Enzyme sites are as 
follows; A, Bam HI; C, Sac I; D, Dra III; E, Eco RI; G, Bgl II; H, Bsp HI; K, Kpn I; L, 
Blp I; P, Sap I; S, Sal I; T, Stu I; U, Bsu 36I.  
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DISCUSSION 
 
 
There is extensive evidence that sheep can provide a viable alternative to current 
animal models of CF (Abraham, 2008; Matute-Bello et al., 2008).  Results from this 
study do not provide insight into the usefulness of sheep as a CF model as was hoped. 
The purpose of this project was to create a founder CF sheep for breeding and 
eventually provide a model for the study of CF treatments. The results show us that none 
of the animals produced were viable and could not be used for breeding.  It is apparent 
that further measures, including negative selection, long arms of homology, and intensive 
screening of cell colonies must be taken to ensure homologous recombination (HR) 
occurs resulting in a healthy and viable heterozygous phenotype (Barzel and Kupiec, 
2008). 
HR is a method used to replace an allele with new gene of interest without 
disrupting other regions within the genome. A major setback to creating animal models is 
the inefficiency of targeted HR.  An HR targeting construct should provide a means to 
insert an engineered mutation into a specific location within the animal’s genome.  The 
mechanisms of HR are poorly understood but the engineered construct will find the gene 
of interest and recombination will occur in a process similar to mechanisms involved 
with meiosis and mitosis. HR occurs at a low frequency in mammalian cells, 
approximately one event per 10
5
 to 10
7
 cells.  Non-homologous recombination (non-HR) 
events occur more than 1,000 times more frequently than HR.  Random insertion occurs 
in about one cell per 10
2
 to 10
4
 transfected cells. With such a high probability of non-HR 
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occurring, targeting constructs must be designed with methods of selection in mind 
(Hanson and Sedivy, 1995; Vasquez et al., 2001).  
New genetic engineering technologies exist that have improved on the rates of 
targeted HR. Transcription activator-like effector nucleases (TALENs) are novel method 
for genetic engineering. TALENs are composed of a DNA binding domain and a Fok I 
domain. The DNA binding domain provides specificity to a targeted DNA sequence 
(Cermak et al., 2011).  It is derived from transcription activator-like effectors (TALEs). 
These proteins derive from a type of bacteria, Xanthomonas, which affects plants and 
functions by directly modifying the host’s genome (Lei et al., 2013). The Fok I domain is 
a restriction endonuclease which introduces a double strand break. In transfected 
fibroblast cell colonies 54% and 17% resulted in mono- or biallelic modifications 
respectively (Carlson et al., 2012). This new technology provides a valid option for 
alternative methods of genetically engineering a model of CF. 
Negative selection is a way to determine which cells have correctly incorporated 
the new DNA. The Diptheria Toxin A (DTA) gene will prevent protein synthesis and was 
used for negative selection in this project. The DTA cassette was placed outside of areas 
of homology within the vector and is not incorporated into the genome when HR occurs. 
Random insertion results in the incorporation of the DTA gene and causes cell death 
(Williams et al., 2003).  
Another important aspect of the gene targeting vector are the long arms of 
homology. These large areas of homology promote the occurance of HR. The longer 
these arms are the higher the chance of HR.  The minimum recommended combined 
length for the two arms is 6-8kb (Hall et al., 2009).  
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The occurance of cleft palate in the ΔF508 lambs show evidence of a genetic or 
epigenetic disruption of an important developmental gene (Mendoza-Londono et al., 
2013).   Understanding the genetic and environmental factors affecting palate formation 
is still a work in progress (Roy et al., 2012) Rapid amplification of cDNA ends (RACE) 
would show where in the genome the construct inserted and could provide insight into 
midline development (Yeku et al., 2011).   
Furthermore, the possibility of multiple insertions must be studied through a 
Southern Blot assay using a probe for the positive selection neomycin cassette. 
New genetic engineering technologies exist that can move this work forward. 
Transcription activator-like effector nucleases (TALENs) are novel method for genetic 
engineering. TALENs are composed of a DNA binding domain and a Fok I domain. The 
DNA binding domain provides specificity to a targeted DNA sequence.  It is derived 
from transcription activator-like effectors (TALEs). These proteins are from a bacteria, 
Xanthomonas, which affects plants and functions by directly modifying the host’s 
genome. The Fok I domain is a restriction endonuclease which introduces a double strand 
break. In transfected fibroblast cell colonies 54% and 17% resulted in mono- or biallelic 
modifications respectively. This new technology provides a valid option for alternative 
methods of genetically engineering a model of CF. 
Due to fertility issues that may present themselves in sheep homozygous for the 
CF mutation, cloning with a female cell line alongside the male cell line would improve 
the outcome of this study. For future use we have prepared tissue biopsies from female 
Romney ewes. They will be transfected using the same techniques for the male cell line.  
  27 
This will provide a female heterozygote to be used in breeding and should result in 
homozygous CF sheep. 
While this particular project did not yield the desired results future measures can 
ensure a successful outcome.  These include a new, efficient genetic modification method 
and extensive cell screening after transfection which should include PCR, restriction 
enzyme digests and Southern Blot assays.  With this in mind it is reasonable to continue 
further research efforts towards creating a sheep model of CF. 
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Figure 2. Lysed ΔF508 embryo chromatogram. The left arrow designates an adenine to 
thymine transition. The right arrow designates the deletion of three thymines.  
 
 
 
  
Figure 3. Lysed G27X embryo chromatogram. The left arrow designates a guanine to 
thymine transition. The right arrow designates a single base pair insertion of cytosine. 
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Figure 4. ΔF508 Lamb DNA chromatogram. The left arrow designates an adenine to 
thymine transition. The right arrow designates the deletion of three thymines. 
 
 
Figure 5. G27X lamb DNA chromatogram. This animal was heterozygous and the 
chromatogram from sequencing results shows a mixture of genotypes. The left arrow 
designates a red peak which represents a guanine to thymine transition. The right arrow 
designates a blue peak which represents a single base pair insertion of cytosine. 
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Ewe # Birth Death Details Necropsy Report 
9089 3/6/13 3/6/13 Euthanized Severe palatoschisis, ventricular septal 
defect, hydronephrosis, myopathy, dilated 
central veins, premature lung, slight cortical 
atrophy 
1002 3/12/13 3/12/13 Stillborn Brachygnathia inferior, palatoschisis, 
hydronephrosis 
1002 3/12/13 3/12/13 Euthanized Brachygnathia inferior, palatoschisis, 
hydronephrosis 
1052 3/12/13 3/12/13 Euthanized Severe palatoschisis, hydronephrosis, 
myopathy, pulmonary atelectasis, lymphoid 
depletion 
1148 3/12/13 3/12/13 Euthanized Brachygnathia inferior, palatoschisis 
1128 3/14/13 3/14/13 Euthanized Brachygnathism, palatoschisis, high 
ventricular septal defect, hydronephrosis, 
myopathy, pulmonary atelectasis, hepatic 
fibrosis, tunica media hypertrophy, 
lymphoid depletion 
9085 3/15/13 3/15/13 Euthanized Severe palatoschisis, brachygnathism,  
hydronephrosis, hemorrhage, myopathy, 
pulmonary atelectasis, hepatic fibrosis, 
tunica media hypertrophy, lymphoid 
depletion 
1128 3/15/13 3/15/13 Stillborn Advanced autolysis precludes meaningful 
interpretation of internal tissues 
1128 3/15/13 3/15/13 Stillborn Advanced autolysis precludes meaningful 
interpretation of internal tissues 
9083 3/18/13 3/18/13 Stillborn Anasarca, brachygnathia inferior, 
palatoschisis, hydronephrosis, ventricular 
septal defect 
Y1057 3/19/13 3/19/13 C-section, 
euthanized 
Hydronephrosis, palatoschisis, 
brachygnathism, high ventricular septal 
defect, tracheal submucosal dysplasia, 
central vein and sinusoid dilation 
Table 1. Synopsis of ΔF508 cloned lamb births. 
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Ewe # Birth Death Details Necropsy 
377 3/14/13 3/14/13 Stillborn prognathism, high ventricular 
septal defect, hydronephrosis, 
myopathy, pulmonary 
atelectasis, hepatic fibrosis, 
tunica media hypertrophy, 
lymphoid depletion 
363 3/22/13 3/22/13 Euthanized tracheal mucosal hyperplasia, 
hydronephrosis, intrabronchiolar 
and intraalveolar rod-shaped 
bacteria   
648 3/24/13 N/A N/A N/A 
Table 2. Synopsis of G27X cloned lamb births. 
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